BeyondSpring Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

BeyondSpring hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.006%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.006%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von BYSI in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von BYSI gestiegen sind.

Dividendenrendite im Vergleich zum Markt

BeyondSpring Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von BYSI im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (BYSI)	n/a
Untere 25 % des Marktes (US)	1.3%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (BYSI) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von BYSI im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von BYSI im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von BYSI, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da BYSI keine Ausschüttungen gemeldet hat.

BeyondSpring Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$0.33 loss in 1H 2023)

New minor risk - Shareholder dilution

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022)

New major risk - Revenue and earnings growth

BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating Activity

New minor risk - Financial data availability

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$2.30

BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Inc. Announces Board Appointments

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic Index

BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022

BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer

Price target decreased to US$6.10

Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring Inc

Consensus forecasts updated

Price target increased to US$13.67

BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022

BeyondSpring, Beyond Salvage

BeyondSpring Pharmaceuticals Announces Organizational Streamlining

Consensus revenue estimates fall by 90%

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and Exposition

Consensus forecasts updated

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

No longer forecast to breakeven

Circling Back On BeyondSpring

Price target decreased to US$58.60

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Price target increased to US$67.25

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Consensus forecasts updated

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Value Index

Consensus forecasts updated

BeyondSpring EPS misses by $0.04

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

BeyondSpring EPS misses by $0.17

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

Chief Scientific Officer has left the company

BeyondSpring Inc. Announces Management Changes

Price target lowered to US$36.00

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

BeyondSpring slides 9% on public offering pricing at $10.0/share

BeyondSpring Announces Positive Topline Results from Its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

BeyondSpring under pressure on shares offering

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

New 90-day high: US$16.02

BeyondSpring Forms Partnership Advisory Committee

New 90-day high: US$15.36

BeyondSpring Inc. Announces JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

BeyondSpring Inc. Announces New Clinical Data on Late-Stage Asset, Plinabulin

BeyondSpring Inc. Appoints Elizabeth Czerepak as Chief Financial Officer

BeyondSpring Inc. to Report Q2, 2020 Results on Sep 03, 2020

New 90-day low - US$10.98